Summary of pharmacokinetic evaluation
Dosage form (dose/unit) | Cmax | tmax | AUC0-24 |
|---|---|---|---|
| ng/ml | h | h · ng/ml | |
| Capsule (100 mg) | |||
| NDioltot | 1.1 (±0.7) | 4.3 (±2.7) | 11.4 (±13.6) |
| NLtot | 4.0 (±2.6) | 2.6 (±2.6) | 33.5 (±24.2) |
| NAtot | 154.8 (±130.8) | 2.8 (±2.3) | 1371.9 (±1365.0) |
| NEtot | 37.7 (±6.9) | 3.8 (±2.6) | 529.1 (±185.7) |
| NLunc | — | — | — |
| Sublingual tablet (25 mg) | |||
| NDioltot | 3.3 (±1.0) | 0.4 (±0.2) | 4.4 (±3.3) |
| NLtot | 11.0 (±6.4) | 0.6 (±0.3) | 15.3 (±7.6) |
| NAtot | 106.3 (±40.1) | 0.9 (±0.3) | 277.9 (±122.9) |
| NEtot | 28.5 (±20.8) | 0.8 (±0.3) | 49.5 (±31.0) |
| NLunc | 4.4 (±1.0) | 0.4 (±0.1) | 5.0 (±1.2) |
—, Only one volunteer generated quantifiable amounts; mean values were not calculated.